Wagner reinforce the expectation that this commission will seek to provide practical, actionable guidance to the administration and the country," says Ruth Faden, executive director of the Berman Institute of Bioethics at the Johns Hopkins University in Baltimore, Maryland. "This is a wise way to structure the leadership of the commission."
The remaining members of the 13-strong commission are expected to include bioethicists specializing in medicine and law, along with experts chosen from the fields of science, engineering, theology and philosophy. Between one and three of those members will be appointed from the government's executive branch. "These appointments, and the council's place in the executive branch of the government, suggests that it will be more than just a talking shop, with perhaps a significant influence over practice," says political theorist Michael Gottsegen of Brown University in Providence, Rhode Island.
Annas believes that the commission may not be sufficiently independent of government. "Bioethics advisory commissions should be totally free-standing, and not linked to the government and presidential terms, in order to avoid doing 'Republican' or 'Democratic' bioethics," he says.
The commission's wider scope will also force some tough choices in deciding priorities, says Annas. "Doctors' [involvement in] force-feeding prisoners at Guantanamo, doctors and torture, and international human-research rules are pressing issues of our day which demand our attention," he says. Among the other issues he thinks the commission should juggle are new reproductive technologies, an overhaul of informedconsent procedures and -perhaps most immediate -fairer ways to apportion health care.
■

Vicki Brower
US bioethics commission promises policy action
The early departure of the head of Britain's Medical Research Council (MRC) has prompted concern for the future of the funding body.
Leszek Borysiewicz announced on 26 November that he will quit as chief executive of the MRC on 1 October 2010 -a year before his four-year term was due to expire -to become vice-chancellor at the University of Cambridge, UK. "It's a thrilling and exciting opportunity for me and one I feel I couldn't resist," says the 58-year-old.
The appointment has generally drawn acclaim for Borysiewicz from Britain's biomedical establishment. Richard Henderson, a researcher at the Cambridge-based MRC Laboratory of Molecular Biology who also sits on the MRC Council, believes that Borysiewicz's background and his political acumen will serve him well in his new role.
But for some, there is also anxiety over the future of the MRC. "I think that Borys has done an excellent job," says Colin Blakemore, a neuroscientist at the University of Oxford, UK, and Borysiewicz's predecessor at the MRC. But Blakemore adds that he is "deeply worried about what this might mean for the MRC, especially for the support of basic biomedical research". Borysiewicz has overseen a major increase in spending, managing a budget that reached £704.2 million (US$1.2 billion) this year. His scientific background, a mix of basic and applied bioscience, has been credited with helping the MRC to increase its emphasis on translational medicine without losing its strength in basic research.
But the future seems less clear. Some believe that the UK government's Department of Health may seek a larger stake in the MRC, pushing it further towards biomedical research and away from fundamental science. There are even worries that the MRC may be absorbed in the Department of Heath, or broken up.
With a general election looming next summer, Borysiewicz's departure "could make the MRC vulnerable at a very critical time", says Blakemore. "It will need a strong new leader, respected by both basic and clinical researchers." But Borysiewicz says he sees little cause for concern. "The MRC is stronger now than it has been for a very long time," he says. 
